NCT00699764View on ClinicalTrials.gov

Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

2,491

Participants

Timeline

Start Date

March 31, 1996

Primary Completion Date

October 31, 1999

Study Completion Date

October 31, 1999

Conditions

Herpes Simplex

Interventions

BIOLOGICAL

Herpes simplex candidate vaccine- adjuvanted GSK208141

Intramuscular injection, 3 doses

BIOLOGICAL

Placebo injection

Intramuscular injection, 3 doses

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00699764 - Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease | Biotech Hunter | Biotech Hunter